VISTAGEN THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VISTAGEN THERAPEUTICS, INC. (VTGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $991.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $991.00K, a 8.19% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.10M, a 1.48% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.10M, a 1.44% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $916.00K, a 21.03% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2026 was $4.00M, a 7.37% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.32M, a 97.75% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.18M, a 34.59% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.34M, a 4.16% decline from fiscal 2022.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $991.00K 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | $4.00M 10-K · filed 2026-06-15 | |||||
| 2025-12-31 | $1.10M 10-Q · filed 2026-02-12 | $2.19M derived: sum of 2 quarters · filed 2026-02-12 | $3.11M derived: sum of 3 quarters · filed 2026-08-14 | |||
| 2025-09-30 | $1.10M 10-Q · filed 2026-02-12 | $2.01M derived: sum of 2 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $916.00K 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | $4.32M 10-K · filed 2026-06-15 | |||||
| 2024-12-31 | $1.08M 10-Q · filed 2026-02-12 | $2.19M derived: sum of 2 quarters · filed 2026-02-12 | $3.35M derived: sum of 3 quarters · filed 2026-02-12 | |||
| 2024-09-30 | $1.11M 10-Q · filed 2026-02-12 | $2.27M derived: sum of 2 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $1.16M 10-Q · filed 2026-02-12 | |||||
| 2024-03-31 | $2.18M 10-K · filed 2025-06-17 | |||||
| 2023-12-31 | $507.00K 10-Q · filed 2025-02-13 | $506.70K 10-Q · filed 2024-02-13 | $1.09M derived: sum of 2 quarters · filed 2025-02-13 | $1.66M derived: sum of 3 quarters · filed 2025-02-13 | ||
| 2023-09-30 | $584.00K 10-Q · filed 2025-02-13 | $583.70K 10-Q · filed 2023-11-09 | $1.15M derived: sum of 2 quarters · filed 2025-02-13 | |||
| 2023-06-30 | $569.00K 10-Q · filed 2025-02-13 | $569.10K 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $3.34M 10-K · filed 2024-06-11 | $3.34M 10-K · filed 2023-06-28 | ||||
| 2022-12-31 | $746.30K 10-Q · filed 2024-02-13 | $1.78M derived: sum of 2 quarters · filed 2024-02-13 | $2.73M derived: sum of 3 quarters · filed 2024-02-13 | |||
| 2022-09-30 | $1.03M 10-Q · filed 2024-02-13 | $1.99M derived: sum of 2 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $956.90K 10-Q · filed 2024-02-13 | |||||
| 2022-03-31 | $3.48M 10-K · filed 2023-06-28 | |||||
| 2021-12-31 | $723.80K 10-Q · filed 2023-02-07 | $1.49M derived: sum of 2 quarters · filed 2023-02-07 | $2.08M derived: sum of 3 quarters · filed 2023-02-07 | |||
| 2021-09-30 | $764.50K 10-Q · filed 2023-02-07 | $1.35M derived: sum of 2 quarters · filed 2023-02-07 | ||||
| 2021-06-30 | $590.40K 10-Q · filed 2023-02-07 | |||||
| 2021-03-31 | $2.31M 10-K · filed 2022-06-23 | |||||
| 2020-12-31 | $730.40K 10-Q · filed 2022-02-10 | $1.14M derived: sum of 2 quarters · filed 2022-02-10 | $1.82M derived: sum of 3 quarters · filed 2022-02-10 | |||
| 2020-09-30 | $410.90K 10-Q · filed 2022-02-10 | $1.09M derived: sum of 2 quarters · filed 2022-02-10 | ||||
| 2020-06-30 | $674.60K 10-Q · filed 2022-02-10 | |||||
| 2020-03-31 | $3.82M 10-K · filed 2021-06-29 | |||||
| 2019-12-31 | $1.63M 10-Q · filed 2021-02-11 | $2.03M derived: sum of 2 quarters · filed 2021-02-11 | $3.09M derived: sum of 3 quarters · filed 2021-02-11 | |||
| 2019-09-30 | $393.50K 10-Q · filed 2021-02-11 | $1.46M derived: sum of 2 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $1.06M 10-Q · filed 2021-02-11 | |||||
| 2019-03-31 | $3.44M 10-K · filed 2020-06-29 | |||||
| 2018-12-31 | $734.70K 10-Q · filed 2020-02-13 | $1.91M derived: sum of 2 quarters · filed 2020-02-13 | $2.52M derived: sum of 3 quarters · filed 2020-02-13 | |||
| 2018-09-30 | $1.17M 10-Q · filed 2020-02-13 | $1.78M derived: sum of 2 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $612.60K 10-Q · filed 2020-02-13 | |||||
| 2018-03-31 | $2.34M 10-K · filed 2019-06-25 | |||||
| 2017-03-31 | $851.30K 10-K · filed 2018-06-26 | |||||
| 2016-03-31 | $4.04M 10-K · filed 2017-06-29 | |||||
| 2015-03-31 | $2.46M 10-K · filed 2016-06-24 | |||||
| 2014-03-31 | $1.14M 10-K · filed 2015-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |